Tyra Biosciences, Inc. — Form SCHEDULE 13D/A
Filed September 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
RA Capital Management, L.P. filed an amended Schedule 13D/A regarding beneficial ownership in Tyra Biosciences, Inc. (NASDAQ: TYRA, market cap ~$297.3M). The filing document itself contains no disclosed changes in ownership percentages, share counts, dollar amounts, or specific transaction details—only administrative metadata indicating the amendment was filed on September 17, 2026. Without access to the actual amended disclosures in the primary document, the specific nature and magnitude of the ownership change cannot be determined.
Why this rating
Amendment to 13D is routine disclosure; without disclosed ownership change specifics, unable to assess materiality. RA Capital's prior stake would need to be stated.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.